The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
- PMID: 33315937
- PMCID: PMC7802955
- DOI: 10.1371/journal.ppat.1009103
The CH1α domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals
Abstract
The antibody molecule comprises a variable domain conferring antigen specificity and affinity distinct from the heavy chain constant (CH) domains dictating effector functions. We here interrogate this paradigm by evaluating the unique influence of the CH1α domain on epitope specificity and functions using two mucosal gp41-specific Fab-IgAs (FabA) derived from HIV-1 highly-exposed but persistently seronegative individuals (HESN). These HESN develop selectively affinity-matured HIV-1-specific mucosal IgA that target the gp41 viral envelope and might provide protection although by unclear mechanisms. Isotype-switching FabAs into Fab-IgGs (FabGs) results in a >10-fold loss in affinity for HIV-1 clade A, B, and C gp41, together with reduced neutralization of HIV-1 cross-clade. The FabA conformational epitopes map selectively on gp41 in 6-Helix bundle and pre-fusion conformations cross-clade, unlike FabGs. Finally, we designed in silico, a 12 amino-acid peptide recapitulating one FabA conformational epitope that inhibits the FabA binding to gp41 cross-clade and its neutralizing activity. Altogether, our results reveal that the CH1α domain shapes the antibody paratope through an allosteric effect, thereby strengthening the antibody specificity and functional activities. Further, they clarify the mechanisms by which these HESN IgAs might confer protection against HIV-1-sexual acquisition. The IgA-specific epitope we characterized by reverse vaccinology could help designing a mucosal HIV-1 vaccine.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.Mucosal Immunol. 2009 Sep;2(5):412-26. doi: 10.1038/mi.2009.89. Epub 2009 Jul 8. Mucosal Immunol. 2009. PMID: 19587640
-
IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.Front Immunol. 2018 Mar 29;9:244. doi: 10.3389/fimmu.2018.00244. eCollection 2018. Front Immunol. 2018. PMID: 29651286 Free PMC article.
-
Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12680-5. doi: 10.1073/pnas.1200024109. Epub 2012 Jun 20. Proc Natl Acad Sci U S A. 2012. PMID: 22723360 Free PMC article.
-
Mucosal correlates of protection in HIV-1-exposed sero-negative persons.Am J Reprod Immunol. 2014 Aug;72(2):219-27. doi: 10.1111/aji.12202. Epub 2014 Jan 16. Am J Reprod Immunol. 2014. PMID: 24428610 Free PMC article. Review.
-
Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization.Curr Opin HIV AIDS. 2017 May;12(3):250-256. doi: 10.1097/COH.0000000000000364. Curr Opin HIV AIDS. 2017. PMID: 28422789 Review.
Cited by
-
Comparison of the Biological Basis for Non-HIV Transmission to HIV-Exposed Seronegative Individuals, Disease Non-Progression in HIV Long-Term Non-Progressors and Elite Controllers.Viruses. 2023 Jun 13;15(6):1362. doi: 10.3390/v15061362. Viruses. 2023. PMID: 37376660 Free PMC article. Review.
-
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.Front Immunol. 2023 Feb 2;14:1037033. doi: 10.3389/fimmu.2023.1037033. eCollection 2023. Front Immunol. 2023. PMID: 36817447 Free PMC article. Review.
-
Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.Front Immunol. 2022 Sep 29;13:842468. doi: 10.3389/fimmu.2022.842468. eCollection 2022. Front Immunol. 2022. PMID: 36248831 Free PMC article.
-
Antibody class-switching as a strategy to improve HIV-1 neutralization.Trends Mol Med. 2022 Nov;28(11):979-988. doi: 10.1016/j.molmed.2022.08.010. Epub 2022 Sep 15. Trends Mol Med. 2022. PMID: 36117072 Free PMC article. Review.
-
Antiviral Activities of HIV-1-Specific Human Broadly Neutralizing Antibodies Are Isotype-Dependent.Vaccines (Basel). 2022 Jun 6;10(6):903. doi: 10.3390/vaccines10060903. Vaccines (Basel). 2022. PMID: 35746511 Free PMC article.
References
-
- Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009;2(5):412–26. 10.1038/mi.2009.89 . - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
